Michael Secora - 09 Feb 2024 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Chief Financial Officer
Signature
/s/ Jonathan Golightly, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
09 Feb 2024
Transactions value $
-$25,346
Form type
4
Filing time
13 Feb 2024, 19:01:59 UTC
Previous filing
18 Jan 2024
Next filing
15 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Award $0 +8,659 +0.88% $0 989,673 09 Feb 2024 Direct F1
transaction RXRX Class A Common Stock Award $0 +174,190 +18% $0 1,163,863 09 Feb 2024 Direct F2
transaction RXRX Class A Common Stock Tax liability -$25,346 -2,512 -0.22% $10.09 1,161,351 09 Feb 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXRX Stock Option (Right to Buy) Award $0 +348,380 $0 348,380 09 Feb 2024 Class A Common Stock 348,380 $10.09 Direct F8
holding RXRX Stock Option (Right to Buy) 685,177 09 Feb 2024 Class A Common Stock 0 $2.22 Direct F4
holding RXRX Stock Option (Right to Buy) 1,035,135 09 Feb 2024 Class A Common Stock 0 $2.22 Direct F5
holding RXRX Stock Option (Right to Buy) 116,684 09 Feb 2024 Class A Common Stock 0 $11.14 Direct F6
holding RXRX Stock Option (Right to Buy) 3,914 09 Feb 2024 Class A Common Stock 0 $11.14 Direct
holding RXRX Stock Option (Right to Buy) 404,857 09 Feb 2024 Class A Common Stock 0 $8.55 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This RSU vested immediately upon the grant date.
F2 This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2024 and every three months thereafter.
F3 Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F4 The option, originally for 1,125,000 shares, vests as to one forty-eighth (1/48th) of the shares subject to the award one month after March 1, 2020, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter.
F5 The option, originally for 1,500,000 shares, vests incrementally upon satisfaction of certain liquidity events.
F6 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F7 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F8 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.